BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the potential of its Prospera Spinal Cord Stimulation (SCS) system.

The Prospera Spinal Cord Stimulation system includes remote monitoring and proactive care. This system integrates RESONANCE multiphase stimulation with automatic, objective, daily remote monitoring and proactive care* to optimize the management of SCS patients’ chronic pain.¹

This system allows real-time therapy adjustments, reducing the need for frequent in-person visits. By facilitating faster issue identification and management, Prospera enables therapy optimization, which may improve long-term outcomes for patients with chronic intractable pain.

BENEFIT-03 was a prospective, multicenter study in Australia that is the first and only long-term clinical trial evaluating the impact of SCS with real-time^† remote monitoring in patients with chronic low back and/or leg pain.

The data showed that participants experienced significant pain relief, along with better sleep, improved function, and reduced opioid medication use. Patients and clinicians reported positive experiences with the Prospera SCS system’s remote monitoring and remote programming capabilities, which enabled rapid resolution of issues to optimize therapy and reduce burdens for patients and clinicians.

Key 12-month interim results included:

• Significant pain relief: At 24 months, therapy responder rates (>50% pain reduction by Visual Analog Scale) were 86% for back pain, 89% for leg pain, and 82% for overall pain.
• Improved daily function: Mean daily pain intensity (by Numerical Rating Scale) was reduced to 1.8 at 24 months vs. 6.6 at baseline, and function was improved with 73% of participants reporting minimal/moderate disability at 24 months (Oswestry Disability Index) vs. 5% at baseline.
• Reduced opioid usage: Among baseline opioid users, 80% eliminated or reduced dosage >50% at 24 months.  
• Rapid issue resolution: Remote monitoring detected SCS issues for all participants, enabling intervention in 2.9 days, vs. more than 7.2 days with standard in-clinic SCS care.² The most common issues were low device usage and therapeutic amplitude outside the prescribed setting.
• Reduced patient time and costs: At 24 months, 95% of participants reported that remote adjustments saved money, and 100% said they allowed more time for daily activities. Clinicians reported remote management reduced staff burdens in the management of 82% of participants and estimated that remote care prevented an average of 5.4 in-office visits per participant through 24 months, with the highest need participants avoiding an average of 12 visits, substantially reducing travel time and costs.
• Serious device- or procedure-related adverse events were rare: Only one such event was reported.

“We’re encouraged to see the continued strong results over time with the Prospera SCS system, which demonstrate its potential to advance patient care and address the challenges SCS patients face,” said Todd Langevin, BIOTRONIK Neuro President. “This evidence reinforces the growing body of research supporting proactive care and remote monitoring as effective strategies to optimize pain relief and mirror the real-world benefits our customers report.”

BIOTRONIK Neuro is the first and only manufacturer to offer daily remote monitoring, automatic objective data transmission, and remote programming in the SCS space. The Prospera SCS system is FDA-approved and available in the U.S.

References:

¹ Naidu, R. K., Kapural, L., Li, S., Tourjé, C., Rutledge, J., Dickerson, D., & Lubenow, T. R. (2025). A Review of the Prospera Spinal Cord Stimulation System with Multiphase Stimulation and Proactive Care. Current pain and headache reports, 29(1), 25. https://doi.org/10.1007/s11916-024-01318-3

² Amirdelfan K, Antony A, Levy R, et al. Health-related and Economic Impacts of Clinic Visit Burdens for Spinal Cord Stimulation Patients and Caregivers. Poster presented at PSPS; September 16-18, 2022; Las Vegas, NV.

*Proactive Care: BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the SCS system based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of SCS proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.

^†With successful data transmission, patient therapy data is available up to the prior 24-hour period